Abstract
The development of blood vessels is essential for organ growth in the embryo and repair of wounded tissue in the adult. However, an imbalance in this process contributes to the pathogenesis of a number of disorders including cancer that is now recognized as the result of not only uncontrolled malignant cell proliferation but also uncontrolled vessel growth. The existence of tumour-derived factors responsible for promoting new vessel growth was postulated over 70 years ago, and a few years later, it was proposed that tumour growth is crucially dependent on neovascular supply. In 1971, pioneering work by Judah Folkmann, who sadly passed away on 14 January 2008, suggested that inhibition of angiogenesis would be an effective strategy to treat human cancer, leading to the development of an active search for angiogenesis inducers and inhibitors. In less than 15 years, an explosion of interest in angiogenesis research has generated the necessary insights to develop the first clinically approved anti-angiogenic agents.1 Several additional common disorders such as psoriasis, arthritis, blindness, obesity, asthma, atherosclerosis, and infectious disease are associated with excessive angiogenesis.2